All relevant data are within the manuscript and its Supporting Information Files.

Introduction {#sec001}
============

Hereditary Hemochromatosis (HH) is a genetic predisposition disease in which the body absorbs and accumulates excess iron from the diet. This excess iron is deposited in certain organs and, if left untreated, can cause tissue damage, the most serious example of which is cirrhosis of the liver, which can lead to liver failure and/or hepatocellular carcinoma and death. Approximately 90% of people with HH are homozygous for a polymorphism in the *HFE* gene (rs1800562) that causes substitution of the amino acid tyrosine for cysteine in the HFE protein at position 282 (p.Cys282Tyr; p.C282Y) \[[@pone.0214196.ref001]\]. The primary biochemical measures of iron status are transferrin saturation (TS), a measure of iron absorption, and serum ferritin (SF), a measure of iron accumulation.

McLaren *et al*. used bivariate mixture modeling to analyze the joint population distribution of transferrin saturation (TS) and serum ferritin concentration (SF) measured for participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study \[[@pone.0214196.ref002]\]. They identified four components (C1, C2, C3, and C4) with successively age-adjusted increasing means for TS and SF from data contributed by more than 100,000 participants of multiple ethnicities. They demonstrated that the bivariate mixture modeling in TS and SF reflect the genetic locus of *HFE* and has the potential to isolate p.C282Y homozygotes from the general population \[[@pone.0214196.ref002]--[@pone.0214196.ref004]\].

In the current study we used data from the another large cohort, the Australian HealthIron study of genetic and environmental modifiers of hereditary hemochromatosis (HH), to validate the component analysis approach, to examine stability of component proportions over time and to determine if TS and SF values from an individual move from one component at baseline to another at follow-up. We note that most new findings require replication before the original report can be considered to have been confirmed. Demonstrating replication is our intent.

Methods {#sec002}
=======

Sources of data {#sec003}
---------------

Between 1990 and 1994, 41,514 people were recruited to participate in the Melbourne Collaborative Cohort Study (MCCS) \[[@pone.0214196.ref005]\]. Baseline blood samples from 31,192 participants of northern European descent (the remainder were from southern European countries such as Greece, Italy, and Malta, populations in which the p.C282Y polymorphism is rare) were genotyped for the p.C282Y and p.H63D polymorphisms in the *HFE* gene. An *HFE*-stratified random sample of these participants (n = 1,438) were selected for invitation to participate in the HealthIron study. Of these, 1,052 participated in interviews and had a clinical examination between 2004 and 2006.

The study originally named "*Genetics modifiers of haemochromatosis phenotype and environmental modifiers of clinical expression of haemochromatosis*" was approved by the Human Research Ethics Committee (HREC) of the Cancer Council Victoria (CCV), Australia as Project No. HREC_0105. The CCV's HREC is a fully-constituted human research ethics committee consistent with the requirements of the Australian National Health and Medical Research Council's "National Statement on Ethical Conduct in Human Research 2007 (Updated 2018)".

The HealthIron participants are an *HFE*-genotype stratified random sample, not a screening cohort, so the sampling fractions from each p.C282Y/p.H63D genotype stratum are not equal. To reflect the *HFE* population proportions, we use frequency weights based on the inverse of the probability of selection for invitation to participate. These weights are 1 for p.C282Y homozygotes (all identified p.C282Y homozygotes were invited to participate), 3 for p.C282Y/p.H63D compound heterozygotes, 10 for p.C282Y simple heterozygotes and 50 for those with no p.C282Y and no p.H63D mutation. Participants who were previously treated for hemochromatosis, missing TS or SF values, missing age, and unknown genotype were excluded.

A data dictionary with variable names and a data spreadsheet are provided in a supporting information file that gives *HFE*-genotypes, demographic variables, and iron indices for HealthIron participants.

Adjusted transferrin saturation and serum ferritin concentration {#sec004}
----------------------------------------------------------------

A restricted cubic spline analysis was used to reflect the non-linear relationships between TS and age \[[@pone.0214196.ref006], [@pone.0214196.ref007]\]. TS values were then adjusted for the age terms using separate multiple linear regression analyses by sex \[[@pone.0214196.ref006]\]. For each individual, the value of the regression residual was calculated and an adjusted transferrin saturation value was computed as the sum of the regression residual and a constant. The constant was calculated as the predicted TS at the median ages, which were 53.8 years at baseline and 65.5 years at follow-up for men, 53.2 years at baseline and 64.1 years at follow-up for women.

The distributions of serum ferritin concentration values were markedly skewed. The natural logarithm transformation was applied to induce the normality of the distributions. Following the same strategy stated above, the adjusted SF values were calculated for each individual at baseline and follow-up separately.

Statistical mixture modeling of the bivariate distribution of TS and SF {#sec005}
-----------------------------------------------------------------------

A complete description of the use of mixture model methodology used to analze the bivariate distribution of TS and SF is provided in McLaren *et al*.\[[@pone.0214196.ref002]\]. In the current study we applied this bivariate mixture modeling approach separately at baseline and follow-up stratified by sex. The EMMIX program, which implements the EM algorithm, was utilized to fit models and to assess the number of normal components \[[@pone.0214196.ref008], [@pone.0214196.ref009]\]. The significance of the likelihood ratio test, the AIC and BIC statistics, and the estimate of overall correct allocation rate were used to determine the number of normal components to best fit the data \[[@pone.0214196.ref010]--[@pone.0214196.ref012]\]. The proportions and the means and variances for adjusted TS and adjusted SF within components of the bivariate distribution were computed. Allocation of each individual to a normal component was obtained at baseline and follow-up based on the highest posterior probability of component membership. A contingency table was constructed to display the shifting in the allocation from baseline to follow-up for individuals by *HFE* genotype, and Bowker's test of symmetry was performed \[[@pone.0214196.ref013]\]. Scatter plots of adjusted TS and SF with 95% confidence ellipses based on the 4-component mixture models were constructed.

Results {#sec006}
=======

The final unweighted analytic sample consisted of TS and SF concentration values from 926 whites (426 men, 500 women) at baseline and in follow−up data from 771 whites (341 men, 430 women) (See [Table 1](#pone.0214196.t001){ref-type="table"}). The final weighted sample included 23328 whites (10261 men, 13067 women) at baseline and in follow−up data from 21,045 whites (9,215 men, 11,830 women). (See [Table 1](#pone.0214196.t001){ref-type="table"}). [Table 2](#pone.0214196.t002){ref-type="table"} displays the participants' characteristics in each analytic cohort. [Table 2](#pone.0214196.t002){ref-type="table"} shows that in the weighted sample, male C282Y homozygotes comprised at follow-up 43% of the initial population (26/60), female C282Y homozygotes comprised at follow-up 68% of the initial population (49/72), and the other genotypes retained 43% of males (9189/10,201) and 68% of females (11,781/12,995). This may indicate that more male C292Y homozygotes were lost for follow-up after initial evaluation and could eventually develop a more severe phenotype.

10.1371/journal.pone.0214196.t001

###### Exclusions for data from participants in the HealthIron study.

![](pone.0214196.t001){#pone.0214196.t001g}

                                                 Unweighted   Weighted                                       
  ---------------------------------------------- ------------ ---------- ----- ----- ------- ------- ------- -------
  Total Sample                                   783          783        655   655   16484   16484   13363   13363
  Excluded for                                                                                               
   Not in Baseline Analysis Cohort               \-           283        \-    229   \-      3417    \-      3102
   Missing values for TS                         255          57         205   60    3331    1222    2931    919
   Missing values for SF                         2            1          3     1     60      3       150     50
   Undetermined *HFE* genotype                   26           0          18    0     26      0       18      0
   Reported previous treated for iron overload   0            12         3     23    0       12      3       27
   Age less than 25 or unknown                   0            0          0     1     0       0       0       50
  Final Analytic Sample                          500          430        426   341   13067   11830   10261   9215

10.1371/journal.pone.0214196.t002

###### Participants' characteristics in the unweighted and weighted analytic samples.

![](pone.0214196.t002){#pone.0214196.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Unweighted    Weighted                                                                                    
  -------------------------------------------------------- ------------- ------------- ------------- ------------- --------------- ----------------- --------------- ----------------
  Number of participants                                   500           430           426           341           13067           11830             10261           9215

  Age-yr, mean (sd)                                        53.8 (9.1)    65.2 (9.3)    54.3 (9.1)    65.9 (9.1)    53.9 (9.3)      65.5 (9.5)        53.9 (9.2)      65.7 (9.2)

  Serum Ferritin (ug/L), median range                      83.5\         112.5\        234.0\        187.0\        77.0\           97.0\             186.0\          162.0\
                                                           (2.0--2781)   (3.0--1260)   (8.0--7134)   (4.0--1613)   (2.0--2781)     (3.0--1260)       (8.0--7134)     (4.0--1613)

  Transferrin Saturation (%), mean (sd)                    32.3 (16.1)   32.1 (14.9)   39.8 (19.1)   35.9 (16.9)   26.3 (9.6)      25.9 (9.6)        31.7 (11.0)     30.7 (11.3)

  Clinical assessment at baseline                                                                                                                                    

   Self-report diabetes, %                                 1 (5/500)     \-            3 (12/426)    \-            1 (163/13067)   \-                3 (328/10261)   \-

   Self-report angina, %                                   2 (9/500)     \-            6 (24/426)    \-            1 (178/13067)   \-                6 (569/10261)   \-

   Self-report heart attack or myocardial infarction, %    1 (6/500)     \-            5 (21/426)    \-            1 (108/13067)   \-                5 (491/10261)   \-

  Clinical assessment at follow-up                                                                                                                                   

   Self-report liver disease, %                            \-            8 (34/419)    \-            3 (11/335)    \-              7 (787/11561)     \-              4 (369/9042)

   Self-report fatigue, %                                  \-            18 (74/421)   \-            10 (32/334)   \-              18 (2081/11614)   \-              11 (1029/9081)

   Abnormal 2^nd^ and 3^rd^ MCP joints on either hand, %   \-            12 (41/354)   \-            16 (48/295)   \-              11 (1048/9785)    \-              17 (1325/8027)

   Liver enlargement, %                                    \-            1 (5/342)     \-            4 (11/289)    \-              2 (154/9359)      \-              4 (287/7901)

  Genotype                                                                                                                                                           

   HO (C282Y homozygote)                                   72            49            60            26            72              49                60              26

   HEHE (C282Y/H63D compound heterozygote)                 75            67            77            63            225             201               231             189

   HEN (C282Y heterozygote)                                122           103           112           90            1220            1030              1120            900

   NHE (H63D heterozygote)                                 63            55            38            35            3150            2750              1900            1750

   NHO (H63D homozygote)                                   8             8             6             6             400             400               300             300

   NN (HFE wildtype)                                       160           148           133           121           8000            7400              6650            6050
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: '-' represents 'not applicable'.

[Table 3](#pone.0214196.t003){ref-type="table"} displays the results of an analysis with four components for both the weighted female and weighted male analytic cohorts, respectively. Although there was some statistical evidence to support the five-component model, we chose to work with the four-component model to aid the comparison of our results with those of previously published research \[[@pone.0214196.ref002]\]. The largest component, C2, had normal mean TS (28% at baseline, 23% at follow-up) and SF (77 μg/L at baseline, 78 μg/L at the follow-up), with component proportion of 0.82 at baseline and 0.63 at follow-up respectively. In the weighted male cohorts, we determined 4 components at baseline and at the follow-up separately. At baseline, the largest component, C2, had normal mean TS value of 31% and a normal mean SF of 243 μg/L. However, at the follow-up, the largest component is C3 with a normal mean TS value of 32% and a normal mean SF of 250 μg/L. [Fig 1](#pone.0214196.g001){ref-type="fig"} displays the scatter plots of adjusted TS and SF values with the indication of p.C282Y homozygotes in red dots from the weighted HealthIron data. The 95% confidence ellipses in black and green color were added based on the results of mixture models from HealthIron and HEIRS data, respectively.

10.1371/journal.pone.0214196.t003

###### The estimated proportions and the means and variances for adjusted TS and adjusted SF within components of the bivariate distribution in the weighted analytic cohort by sex.

![](pone.0214196.t003){#pone.0214196.t003g}

  Cohort                          Mixture component   Estimate of mixing proportion   Estimated adjusted mean TS (%)   Estimated adjusted TS variance   Estimated adjusted mean SF (ug/L)   Estimated adjusted mean SF (ug/L) in original scale[^1^](#t003fn001){ref-type="table-fn"}   Estimated adjusted SF variance
  ------------------------------- ------------------- ------------------------------- -------------------------------- -------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------- --------------------------------
  Women at Baseline N = 13,067    C4                  0.003                           77.060                           43.834                           5.344                               209.369                                                                                     0.592
  C3                              0.057               46.735                          43.834                           4.993                            147.304                             0.592                                                                                       
  C2                              0.821               28.351                          43.834                           4.338                            76.524                              0.592                                                                                       
  C1                              0.118               16.299                          43.834                           2.638                            13.984                              0.592                                                                                       
  Women at Follow-up N = 11,830   C4                  0.009                           61.187                           36.233                           5.049                               155.804                                                                                     0.724
  C3                              0.288               35.218                          36.233                           5.185                            178.573                             0.724                                                                                       
  C2                              0.627               23.479                          36.233                           4.351                            77.587                              0.724                                                                                       
  C1                              0.076               12.083                          36.233                           2.384                            10.853                              0.724                                                                                       
  Men at Baseline N = 10,261      C4                  0.010                           77.955                           56.098                           5.671                               290.441                                                                                     0.477
  C3                              0.160               47.121                          56.098                           5.513                            247.819                             0.477                                                                                       
  C2                              0.686               31.046                          56.098                           5.454                            233.668                             0.477                                                                                       
  C1                              0.145               24.993                          56.098                           3.831                            46.104                              0.477                                                                                       
  Men at Follow-up N = 9,215      C4                  0.068                           55.619                           62.295                           5.472                               237.959                                                                                     0.547
  C3                              0.638               32.073                          62.295                           5.522                            250.135                             0.547                                                                                       
  C2                              0.234               26.722                          62.295                           3.953                            52.097                              0.547                                                                                       
  C1                              0.060               14.619                          62.295                           2.503                            12.219                              0.547                                                                                       

^1^Estimated adjusted SF in original scale = exp^(Ln(SF))^

![Scatter plots of adjusted TS and SF with indication of the C282Y homozygote cases as red dots from HealthIron study.\
The 95% confidence ellipses in black and in green were based on the 4-component models from HealthIron and HEIRS data, respectively. The weighted analytic cohorts: A. Female at baseline, B. Female at follow-up, C. Male at baseline and D. Male at follow-up.](pone.0214196.g001){#pone.0214196.g001}

Female p.C282Y homozygotes showed evidence that component transition probabilities shifted significantly over time; 29% had TS and SF values that were in the same bivariate TS/SF component at baseline and follow−up (Bowker's test of symmetry, p = 0.03). For the other genotypes, the percentages of females who had TS and SF values that were in the same bivariate component at baseline and follow−up were 40% for p.C282Y/p.H63D compound heterozygote, 47% for p.C282Y heterozygotes, 49% for p.H63D heterozygotes, 75% for p.H63D homozygotes and 68% for *HFE* wildtype. In the male cohort, the percentages of participants whose TS and SF values were in the same bivariate component at baseline and follow−up varied from 33% to 77% by genotype (Bowker's test of symmetry, all p-values \< 0.0001, except for p.C282Y homozygotes where p = 0.33) (see Tables [4](#pone.0214196.t004){ref-type="table"} and [5](#pone.0214196.t005){ref-type="table"}).

10.1371/journal.pone.0214196.t004

###### The contingency table of baseline versus follow-up group membership among females (N = 11830).
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  ------------------------ ------------------------- ------- ------- ----------- -------
  **Baseline component**   **Follow-up Component**                               
  **1**                    **2**                     **3**   **4**   **Total**   
  1                        150                       736     283     6           1175
  2                        490                       6823    2724    35          10072
  3                        60                        165     295     45          565
  4                        0                         2       9       7           18
  Total                    700                       7726    3311    93          11830
  ------------------------ ------------------------- ------- ------- ----------- -------

10.1371/journal.pone.0214196.t005

###### The contingency table of baseline versus follow-up group membership among males (N = 9215).

![](pone.0214196.t005){#pone.0214196.t005g}

  ------------------------ ------------------------- ------- ------- ----------- ------
  **Baseline component**   **Follow-up Component**                               
  **1**                    **2**                     **3**   **4**   **Total**   
  1                        273                       399     380     101         1153
  2                        236                       1416    4964    244         6860
  3                        50                        146     775     161         1132
  4                        0                         51      1       18          70
  Total                    559                       2012    6120    524         9215
  ------------------------ ------------------------- ------- ------- ----------- ------

Discussion {#sec007}
==========

We applied bivariate mixture modeling to analyze joint population distributions of TS and SF measured in the HealthIron Study. We identified four components with successively age-adjusted increasing means for TS and SF at baseline and follow-up data by sex, separately. In the weighted female analytic cohorts, C4 captured most of p.C282Y homozygotes, and C2 was the largest component. In our study at baseline and follow-up, the means of adjusted TS and SF within components were higher than the means from HEIRS data. The estimated variances from the HealthIron data were much smaller than the estimated variances from HEIRS. In addition, we identified 4 components from the weighted male analytic cohort and C4 captured most of the p.C282Y homozygotes. Therefore, the bivariate mixture modeling approach suggested that the model is transferable from one white population to another, although estimated means within components may differ. The longitudinal aspect of this study is unique and illustrates that, with the exception of female p.C282Y homozygotes, the components of the mixture distributions are largely stable over time.

Strengths of this study include the prospective nature of recruitment for both the HEIRS and HealthIron studies and the comprehensive phenotyping through multiple sources: self-completed questionnaires, standardized biochemical analysis of all blood and tissue samples, and comprehensive clinical examination of participants by study physicians. Weaknesses include the different circumstances, motivations and time periods under which the two cohorts were recruited, and the different sampling fractions for each *HFE*-genotype group in the HealthIron study. This required the use of frequency weights to implement the mixture model analysis for which only approximate measures of precision of estimation are available.

In conclusion, our study provides another demonstration of the usefulness of mixture modeling in determining the presence and estimating the frequency of subpopulations in an overall population distribution. A unique aspect of our investigation was the access to longitudinal data enabling determination of subpopulation components at baseline and follow-up and assessment of a shift of component probabilities over time. A significant shift between baseline and follow-up was found for female p.C282Y homozygotes but not for male p.C282Y homozygotes.

Supporting information {#sec008}
======================

###### A data dictionary with variable names and a data spreadsheet are provided in a supporting information file.

The data spreadsheet gives *HFE*-genotypes, demographic variables, and iron indices for HealthIron participants.

(XLS)

###### 

Click here for additional data file.
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